Rock Spring Ventures
Rock Spring Ventures (RSV) invests in early-stage, high-growth health science companies in under-ventured markets in the US and in the UK. RSV invests via a two fund structure, including its Bethesda, Maryland-based fund Rock Spring Ventures, LP and its Edinburgh, Scotland-based fund Rock Spring Ventures EU LP, respectively. RSV's focus is on providing equity capital to young companies including university spin-outs that are currently developing commercial applications of novel research.
RSV's international management team has a track record of successfully partnering with scientists and entrepreneurs to develop highly innovative products for the global healthcare market. RSV's management team brings extensive relationships, industry and operating experience and a disciplined investment approach.
RSV believes in working closely with the management of its portfolio companies to more effectively translate their research into commercial, patient-driven applications. RSV's global network of investment professionals, scientists, operating executives, health practitioners, policy experts, regulatory advisors and business development leaders contributes significantly to the growth and development of RSV's portfolio companies.
RSV also places a particular emphasis on the importance of international business development. Uniquely, RSV's global network includes several of Japan and Korea's leading corporations and financial institutions. These partners help provide an important bridge to key markets in East Asia, thereby further supporting the international growth of RSV's investees. These partners are particularly helpful for high-growth companies in the UK and US that are seeking further clinical validation and the establishment of sales and distribution strategies for the Japanese and Korean markets.
With funds in the US and UK, RSV is particularly interested in UK and US early-stage, high-growth companies developing technologies with outstanding prospects for today's global healthcare market.